MannKind burns through $23.3 million in cash
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Sienna stock soars after $65 million IPO
Westlake Village biotechnology company Sienna Biopharmaceuticals closed with a big gain after it raised $65 million in its initial public offering July 27. Sienna priced the 4.33 million shares it offered at $15. Shares had reached $21 around noon before ending at $19.25, a 28.3 percent premium on its opening price. The company operates in Read More →
Read More →Sienna Biopharmaceuticals files for $75 million IPO
Westlake Village biotechnology company Sienna Biopharmaceuticals filed for an initial public offering with the Securities and Exchange Commission on June 3, stating expectations to raise up to $74.75 million. Founded in 2010, the company develops clinical-stage topical therapies for inflammatory skin diseases and other conditions. ARCH Venture Partners and Venvest Capital led a $40 million Read More →
Read More →MannKind hires financial adviser after boosting cash on hand
MannKind, a Southern California biotechnology company heading to Westlake Village, hired Greenhill & Co. as a financial and strategic adviser June 28, after requesting the last of its line of credit through a loan from the Mann Group. The company will draw on the remaining $30.1 million of funding, using $10.6 million to capitalize unpaid Read More →
Read More →Thousand Oaks’ Ceres sees stock price spike after patent approved
Ceres, a Thousand Oaks based agriculture-biotechnology company, saw shares spike 373 percent Wednesday after the company received a patent for its iCODE multi-gene trait development system. Ceres shares started the day at just 95 cents per share, and soared all the way to $4.80 when the markets opened at 6:30 a.m. PST. Ceres closed the Read More →
Read More →Amgen to slash 2,400 jobs, shrink Thousand Oaks HQ
Thousand Oaks-based Amgen will cut staff at its Conejo Valley headquarters and consolidate into fewer buildings as part of a company-wide restructuring plan that will eliminate between 2,400 and 2,900 jobs and shutter facilities in Colorado and Washington. Amgen said the moves are designed to reduce operating expenses by $700 million by 2016, money that Read More →
Read More →
Sponsored content:
2015-2016 Giving Guide
